The pitfalls of platform comparison: DNA copy number array technologies assessed.

Area of Science:

• Genomics and Bioinformatics
• Cancer Research
• Molecular Biology

Background:

• Accurate DNA copy number aberration mapping is crucial for understanding tumor development.
• No single platform is universally accepted for high-resolution genomic studies.
• Previous comparisons often used outdated methods or less complex samples, introducing bias.

Purpose of the Study:

• To systematically compare the performance of four leading microarray platforms for DNA copy number aberration detection.
• To provide a fair assessment of platform performance by minimizing inherent biases.
• To guide the selection of optimal platforms for cancer research and study design.

Main Methods:

• Comparative analysis of four microarray platforms: Affymetrix, Agilent, Illumina, and Nimblegen.
• Utilized samples from primary breast tumors, cancer cell lines, and HapMap individuals.
• Assessed reproducibility, noise, sensitivity, and detection of aberrations of varying sizes, while controlling for bias.

Main Results:

• Nimblegen showed significantly higher between-replicate variances compared to other platforms.
• Agilent demonstrated the highest sensitivity for detecting copy number variations.
• All platforms robustly detected large aberrations, but smaller focal events were inconsistently identified.

Conclusions:

• Despite design differences, a high concordance exists between platforms, though reproducibility and sensitivity vary.
• Agilent is recommended as the top array-CGH platform, and Affymetrix as the superior SNP-CGH platform.
• This study offers guidance for platform selection and study design in copy number aberration analysis.